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BACKGROUND Catheter-based renal artery denervation therapy has
become established as a therapeutic option in patients with resistant
hypertension. We further investigated the safety and performance of
the next generation EnligHTN Renal Denervation System (St. Jude
Medical) in patients with drug-resistant hypertension.
METHODS The EnligHTN Renal Artery Ablation Catheter has 4
electrodes attached on a basket mounted at the tip of the catheter.
The basket is collapsed and can be expanded via an external mecha-
nism once the catheter is placed in the desired location of the renal
artery. The next generation EnligHTN RF Ablation Generator
utilizes a novel algorithm for the delivery of 1 minute of radio-
frequency energy, optimized for simultaneous delivery of therapy
through all 4 electrodes, with an interactive, intuitive user interface.
Renal denervation was performed on 39 patients across 6 centers
meeting the following inclusion criteria: 18-80 years of age, a
systolic BP 160 mmHg, an average daytime systolic ambulatory
BP 135 mmHg, on three or more antihypertensive agents (including a
diuretic), and renal artery diameter 4mm and length 20mm. The
primary endpoints are 1) to characterize the rate of serious procedural
and device related adverse events from date of procedure through 6
months post procedure and 2) the change in ofﬁce BP at 6 months post
procedure. The secondary endpoints include the changes in 24 hour
ambulatory BP and the characterization of renovascular safety and
renal function change over time from baseline. Renal artery CT angi-
ography was repeated at 6 months in all patients. The multi-electrode
ablation catheter was introduced into each renal artery and two sets of
denervation therapy delivered per renal artery.
RESULTS To date 37/38 patients have completed 18-months of follow-
up post procedure. One serious device or procedure related adverse
event, a pseudo aneurysm, has been observed as adjudicated by an
independent Clinical Events Committee. There were no clinically
signiﬁcant changes in renal function through 18-months as observed
in eGFR, serum creatinine, cystatin C, or urine albumin-to-creatinine
ratio. 18-month ofﬁce (and 12M, 24 hour ambulatory) BP reductions
from baseline were -25/-8 (-11/-4) mmHg, which were statistically
signiﬁcant except for the ambulatory diastolic reduction. Renal artery
denervation procedures were performed successfully in all patients,
with an average of 4.33 ablation sets and 15.85 ablations performed
per patient. The mean total ablation catheter insertion-to-removal
time was 22.38 min and mean ablation time was 4.33 min per patient.
CONCLUSIONS Accumulated 24-month results from all sites will be
presented at the meeting. After 18-months follow-up post procedure
in this ﬁrst-in-human study, we conclude that data demonstrates the
next generation EnligHTN Renal Denervation System continues to be
safe, rapid, and effective in the treatment of patients with drug-
resistant, uncontrolled hypertension.
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BACKGROUND The Kona Medical Surround Sound System is a non-
invasive device for renal denervation that delivers externally focused
ultrasound to the renal nerves using Doppler-based image guidance to
track and correct for renal artery motion during the procedure. Aims:
To evaluate the safety and efﬁcacy of an entirely non-invasive
approach to renal denervation using externally delivered focused ul-
trasound with real time Doppler-based image guidance in treatment
resistant hypertension (TRH).
METHODS In 3 consecutive studies 69 patients with severe TRH,
deﬁned as persistent systolic blood pressure (BP) > 160 mmHg
despite 3 or more antihypertensive medications, were treated non-
invasively with the Kona Medical Surround Sound System. Focused
ultrasound energy was delivered to the renal arteries bilaterally and
surrounding tissue using Doppler-based imaging and continuous
tracking with automatic correction for kidney motion throughout
treatment. Patients received conscious sedation during the treatment
period.
RESULTS At this time, all patients have completed 24 weeks
follow-up and 61 patients have completed 52 weeks of follow-up.
Post-denervation, the mean changes from baseline BP were -16.2/-
6.7 mmHg at 3 weeks, -22.3/-9.0 mmHg at 6 weeks, -24,4/-9.9 mmHg
at 12 weeks, -24.6/-9.0 mmHg at 24 weeks and -22.9/-9.9 mmHg 52
weeks . Response rates (drop in BP by > 10 mmHg) was 75% at 6
and 12 months. No serious intervention related events have been
reported to date. Forty-six percent of subjects (32/69) reported mild
back pain immediately following the denervation treatment. The
majority of cases (19/32) completely resolved within seven days post
treatment and no case was associated with any motor, sensory
deﬁcits.
CONCLUSIONS This is the ﬁrst data in humans using a non-invasive
renal denervation system in severe TRH. Results showed clinically
meaningful reductions in ofﬁce BP through 52 weeks post-denerva-
tion. The procedure was well-tolerated with no serious adverse
events. Sham-operator controlled studies with the Kona systems to
evaluate the safety and efﬁcacy of this novel non-invasive treatment
are in the recruiting and planning stages.
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BACKGROUND Despite recent setbacks and limitations with radio-
frequency (RF)-based therapies, there is continued interest in
renal denervation as a therapy for uncontrolled hypertension. We
present an update of targeted “chemical renal denervation” using
alcohol as the neurolytic agent, as an alternative method for renal
denervation.
METHODS The Peregrine System is a novel endovascular catheter
with three micro-needles which are deployed into the perivascular
